IL2 and kidney cancer: Renal cell carcinoma (RCC), a common type of kidney cancer, is remarkably resistant to radiation therapy, chemotherapy and cytokine immunotherapy (including, interferon α/γ, interleukin-2) with a response rate of less than 20%.